The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through rapid, non-destructive spectroscopy for continuous monitoring, eliminating analytical delays, and enabling predictive, closed-loop control.

Traditional upstream and downstream processes (USP and DSP) rely on slow, episodic measurements that introduce control lag. In upstream operations, delayed insight into nutrient and metabolite dynamics can compromise cell health and productivity, while in downstream workflows, late quality measurements can lead to suboptimal purification decisions and yield losses. Spectroscopic PAT replaces off-line testing with continuous or near–real-time molecular insight across the bioprocess lifecycle.

In upstream processing, Raman spectroscopy enables automated nutrient control by translating in situ spectral fingerprints of key metabolites into actionable concentrations via multivariate models. In downstream processing, spectroscopic techniques such as multi-dimensional fluorescence and Raman provide rapid, non-destructive insight into critical quality attributes, supporting faster decisions and reduced reliance on off-line assays.

While Raman excels at bulk chemical monitoring, complex biopharmaceutical products require higher molecular specificity. Absorbance-Transmission Excitation-Emission Matrix (A-TEEM) spectroscopy for high-specificity characterization integrates absorbance, transmittance, and excitation-emission fluorescence into a single rapid measurement, generating sensitive three-dimensional molecular fingerprints that extend PAT from process monitoring to detailed molecular characterization across both USP and DSP.

Tackling sample concentration limits

To overcome the inner filter effect (IFE) in concentrated samples, A-TEEM uses absorbance data to mathematically correct fluorescence intensities. This linearizes the response from ppb to mg/mL, enabling label-free, specific quantification of key components like aromatic amino acids and vitamins in concentrated biologics.

Importantly, the technique is insensitive to the fluorescence of common process compositions like water and simple sugars (e.g., glucose). This natural high selectivity simplifies the analysis of complex media and formulation samples. The resultant A-TEEM is a unique, three-dimensional spectral contour map (Figure 1), serving as a comprehensive molecular fingerprint for qualitative and quantitative analysis via multivariate analysis (MVA) tools like Parallel factor analysis (PARAFAC) and Principal component analysis (PCA).

Reliance on intrinsic fluorescence means that A-TEEM measurements do not require complex labeling steps. Detectable fluorophores are essential for biological function and exhibit distinct spectral features, as detailed in Table 1.

The technique exhibits high selectivity because molecules commonly found in large concentrations in bioprocesses (e.g., water, simple sugars) lack intrinsic fluorescence in the analytical range, thus providing negligible background interference.

Deconvolution of complex data

Complex bioprocess samples generate overlapping spectral signals that require multivariate analysis to extract meaningful chemical information. Two powerful tools commonly applied to A-TEEM datasets are PARAFAC and PCA.

PARAFAC resolves overlapping fluorophores into individual spectral components with concentration-like scores, enabling quantitative modeling across different samples. Its sensitivity to subtle spectral changes allows discrimination between fluorophore microenvironments, such as solvent-exposed versus buried tryptophan, providing critical insight into protein structural integrity and stability.

PCA, applied to unfolded A-TEEM datasets, captures the major sources of variance and uncovers latent structure within the data. While PCA components are not inherently chemically interpretable, they support pattern recognition, clustering, outlier detection, trend visualization, and classification, allowing rapid identification of process deviations or sample similarities across both upstream and downstream workflows.

Mastering biopharmaceutical quality

By leveraging A-TEEM technology, manufacturers are gaining unprecedented insights into protein stability, metabolic kinetics, and complex characterization.

1. Real-time protein stability tracking under thermal stress

Protein stability is a critical quality attribute (CQA) that directly correlates with therapeutic efficacy and shelf life. A-TEEM provides a label-free, continuous method to track protein degradation and aggregation.

In a study of monoclonal antibody (mAb) API stability, samples were monitored continuously for over 100 hours at elevated temperatures. The resulting A-TEEM fingerprints revealed two concurrent phenomena. First, early chemical degradation was signaled by a red shift in tryptophan emission and a decrease in fluorescence intensity. This shift reflects the unfolding process, as buried tryptophan residues become exposed to the polar solvent. Second, as thermal stress continued, new visible-range spectral features emerged-likely representing oxidative degradants or early aggregation chromophores.

By simultaneously monitoring multi-dimensional profiles (Figure 2), A-TEEM allows for the early identification of degradation kinetics, providing the data necessary to predict long-term shelf-life limitations with high precision.

2. Decoding metabolic tracking and reaction kinetics

Beyond stability, A-TEEM serves as a powerful tool for monitoring the dynamics of biological and chemical reactions. Its sensitivity to fluorophore shifts provides deep mechanistic insight into complex processes like T-cell expansion. In these cultures, shifts in the A-TEEM fingerprints, (Figure 3), specifically within the NAD(P)H region, show a direct correlation with Total Viable Cell Count (TVCC).

The technology is equally effective in tracking conjugation reactions. For instance, during the conjugation of the CRM 197 carrier protein with pneumococcal polysaccharides, the reaction’s progress can be tracked via two distinct events: the quenching of intrinsic protein fluorescence and the birth of a new, weaker fluorescence band characteristic of the newly formed covalent bond¹.

3. Advancing mAb and AAV characterization

The precision of A-TEEM allows for the differentiation of highly similar bioproducts that traditional methods might miss. In mAb characterization, MVA models can successfully discriminate between samples with up to 95% sequence similarity based on subtle tryptophan fluctuations. Furthermore, IFE-corrected data enables quantitative models, such as PARAFAC, to accurately measure individual components within binary mixtures across broad concentration ranges.

This sensitivity extends to the cutting edge of gene therapy: AAV titer and full/empty (F/E) ratio quantification. Because the packaged DNA payload acts as an internal quencher, full capsids produce a lower protein signal compared to empty capsids. This allows for a rapid, label-free method to determine the F/E ratio, which is a vital metric for viral vector efficacy.

A unified PAT strategy

The future of bioprocessing lies in the integration of diverse analytical tools. By combining the real-time process control of Raman spectroscopy with the molecular specificity of A-TEEM, manufacturers can implement a predictive, end-to-end PAT strategy. Spanning both upstream and downstream operations, this holistic approach links process dynamics directly to product quality, ensuring a more consistent and efficient manufacturing lifecycle.

Reference

1. Saha-Shah, A., Smith, J.P., Konietzko, J., Costell, E., McHugh, P.M., Lo-Mont, J.P., Ralbovsky, N.M., Obando, L., Wang, S.C., Appiah-Amponsah, E. and Mangion, I., 2023. Real-time in situ monitoring of CRM-197 and polysaccharide conjugation reaction by fluorescence spectroscopy. Bioanalysis, 15(9), pp.493-501.

Lyufei Chen, PhD, is an application scientist at HORIBA Scientific.